BATOPROTAFIB

also known as TNO155 · PTPN11 INHIBITOR TNO155 · SHP2 INHIBITOR TNO155

Small molecule targets PTPN11 via inhibition

Developed for: non-small cell lung carcinoma · colorectal cancer · esophageal squamous cell carcinoma · gastrointestinal stromal tumor · head and neck squamous cell carcinoma · cancer · cancer of unknown primary site · colorectal carcinoma
+3 more
· cutaneous melanoma · metastatic malignant neoplasm · lung cancer
Investigated by: Novartis Pharmaceuticals · Pharmaceutical Research Associates · Amgen · Array BioPharma · Massachusetts General Hospital · Mirati Therapeutics Inc.
+2 more
· Novartis · Pfizer

Trials 10 · a red edge is where a trial was stopped

today NCT07468071 · Ph 1/2 NCT05541159 · Ph 1 NCT05490030 · Ph 1 NCT04699188 · Ph 1/2 NCT04294160 · Ph 1 NCT04292119 · Ph 1/2 NCT04330664 · Ph 1 NCT04185883 · Ph 1 NCT04000529 · Ph 1 NCT03114319 · Ph 1

201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT05541159	Mar → Jul 2025	impaired renal function disease	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 1	NCT05490030	Mar → Jun 2025	—	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 1	NCT04294160	Jul 2020 → Sep 2024	colorectal cancer	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 1	NCT04330664	Apr 2020 → Jul 2022	cancer of unknown primary site, metastatic malignant neoplasm	Mirati Therapeutics Inc.	Completed	No outcome recorded
Phase 1	NCT04185883	Dec 2019 → Dec 2026 expected	cancer	Amgen	Active not recruiting	No outcome recorded
Phase 1	NCT04000529	Jul 2019 → Jan 2024	colorectal cancer, esophageal squamous cell carcinoma, gastrointestinal stromal tumor, head and neck squamous cell carcinoma +1	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 1	NCT03114319	May 2017 → Jul 2025	cutaneous melanoma, esophageal squamous cell carcinoma, gastrointestinal stromal tumor, head and neck squamous cell carcinoma +1	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT07468071	Jun 2026 → Jun 2029 expected	—	Novartis Pharmaceuticals	Recruiting	No outcome recorded
Phase 1/2	NCT04699188	Feb 2021 → Jan 2027 expected	colorectal carcinoma, non-small cell lung carcinoma	Novartis Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 1/2	NCT04292119	May 2020 → Dec 2022	non-small cell lung carcinoma, refractory malignant neoplasm	Massachusetts General Hospital	Unknown	No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	BATOPROTAFIB	ChEMBL registry synonym — accepted as the source's own label CHEMBL4650521 ↗
Known as	PTPN11 INHIBITOR TNO155	ChEMBL registry synonym — accepted as the source's own label CHEMBL4650521 ↗
Known as	SHP2 INHIBITOR TNO155	ChEMBL registry synonym — accepted as the source's own label CHEMBL4650521 ↗
Known as	TNO155	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04000529 ↗ 9 NCT04294160 ↗ NCT07468071 ↗ NCT04292119 ↗ NCT04699188 ↗ NCT03114319 ↗ NCT05541159 ↗ NCT05490030 ↗ NCT04330664 ↗ NCT04185883 ↗
Action	Inhibit	“Protein-tyrosine phosphatase 2C inhibitor” CHEMBL4650521 ↗ 1 “SHP2 inhibitor TNO155” NCT03114319 ↗
Modality	Small molecule	— CHEMBL4650521 ↗
Route	Oral	“TNO155 for oral administration” NCT03114319 ↗
Target	PTPN11	“Protein-tyrosine phosphatase 2C inhibitor” CHEMBL4650521 ↗